Research programme: recombinant antibody mixtures - Symphogen
Alternative Names: Anti-RSV rpAb; Anti-vaccinia virus rpAb; Sym 002; Sym 003; Sym 005; Sym 007; Sym 008Latest Information Update: 07 Jun 2023
At a glance
- Originator Symphogen
- Developer Genentech; Symphogen
- Class Monoclonal antibodies; Polyclonal antibodies; Recombinant proteins
- Mechanism of Action ERBB 2 receptor modulators; Immunoglobulin stimulants; Immunomodulators; Immunostimulants; Receptor protein-tyrosine kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Hypersensitivity; Infections; Respiratory syncytial virus infections; Smallpox